Lung Cancer Screening and COPD Update

Michael T. Vest, DO, FACP, FCCP
Assistant Professor of Medicine
Pulmonary and Critical Care Medicine
Christiana Care Healthcare System
Newark, DE
Sidney Kimmel Medical College
Philadelphia, PA
Objectives

• Lung Cancer Screening
  – Describe benefits of lung cancer screening
  – List who should and should not be screened

• COPD Updates
  – Understand use of beta blockers in COPD
  – Describe role for inhaled steroids in COPD and discuss data on eosinophils as it relates to inhaled steroids
  – Describe role of NIPPV in outpatients chronic hypercarbic respiratory failure
Nodule Versus Mass

- Nodule: less than 3 cm
  - The larger the nodule, the more likely malignant
  - The older the patient, the more likely malignant
  - The more lung CA risk factors: age, smoking, radon, occupational (asbestos)
  - Pattern radiographically (upper v. lower lobe, spiculation, eccentric calcification v. popcorn calcification)
  - History of extrathorax malignancy

- Mass: greater than 3 cm
  - Malignant till proven otherwise
Nodules

- Most nodules less than 0.8 cm are benign
- Most nodules greater than 2 cm are malignant
Doubling Time in Lung Cancer

• Doubling time is the time it takes a group of cells to double in size
• 30 doublings are needed to get to 1 cm size
• Doubling time varies from 30 to >400 days ("2 year rule")
• 26% increase in diameter corresponds to a doubling in volume (so more time may be needed before increase in size can be seen on CT)
Lung Cancer Screening

- NLST (NEJM 2011; 365: 395-409)
- Number Needed to Screen 320 to prevent one death
- 20% relative risk reduction
- Inclusion criteria
  - Age 55-74, >30 pack year history of smoking, quit less than 15 years ago or current smoker
- 39% of patients in CT screening had nodules
- Overall mortality
  - “There were 1877 deaths in the low-dose CT group, as compared with 2000 deaths in the radiography group, representing a significant reduction with low-dose CT screening of 6.7% (95% CI, 1.2 to 13.6) in the rate of death from any cause (P=0.02).”
USPFT Recommendation

- Grade B Recommendation Applies to:
  - Asymptomatic Adults
  - 55-80 years old
  - ≥ 30 pack year history of smoking
  - Current smoker or quit smoking <15 years ago

- Recommendation
  - Annual low dose computer tomography
  - Stop screening once pt has stopped smoking for 15 years, develops health condition that limits ability to get treatment or is no longer willing to undergo surgery or curative intent radiation

Other organizations

• American Cancer Society, American College of Chest Physicians, American Society of Clinical Oncology, American Thoracic Society, American Cancer Society, International Association for the Study of Lung Cancer, American Lung Association
  – Ages 55-74 with ≥30 pack years, quit<15 years or still smoking
  – ACCP has changed age recommendation to 55-77

• National Comprehensive Cancer Network
  – Recommends same as above but also recommends screening individuals with ≥ 20 pack year history and one additional risk factor (COPD, pulmonary fibrosis, other smoking related cancer)

• American Academy of Family Physician
  – The evidence is insufficient to recommend for or against lung cancer screening by low dose CT
Lung Cancer Screening Uptake

• Data from National Health Interview Survey
  – 36,191 people questions about CT scan for lung cancer screening, smoking status
  – Among high risk smokers, 5.8% on 2015 survey reported screening CT scan
    – JAMA Internal Medicine 2017; 177: 439-441

• Editorial in American Journal of Public Health
  – “…the dismal uptake of low-dose CT screening through physician-focused efforts suggests that the public health community needs to champion low-dose CT screening and embrace its cost-effectiveness.”
    – AJPH Oct 2018; 108: 1292-1293
# Lung Cancer versus other cancer screening

<table>
<thead>
<tr>
<th>Screening intervention</th>
<th>Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammography, ages 40-49</td>
<td>3 lives saved per 10,000 screened</td>
</tr>
<tr>
<td>Mammography, ages 50-59</td>
<td>8 lives saved per 10,000 screened</td>
</tr>
<tr>
<td>Mammography, ages 60-69</td>
<td>21 lives saved per 10,000 screened</td>
</tr>
<tr>
<td>Mammography, ages 70-74</td>
<td>13 lives saved per 10,000 screened</td>
</tr>
<tr>
<td>Colonoscopy every 10 years</td>
<td>24 lives saved per 1000 screened</td>
</tr>
<tr>
<td>Lung cancer NLST population</td>
<td>3 lives saved per 1000 screened</td>
</tr>
</tbody>
</table>

Lung cancer screening out-performs mammography in terms of lives saved.

Colonoscopy: JAMA 2016; 315: 2564-2575
Reasons for low uptake of lung cancer screening among eligible patients

• Patient Factors
  – Fear, nihilism, guilt from having smoked

• Physician Factors/Health System Factors
  – Knowledge about screening
  – Requirements for shared decision making
  – Incidental findings
Do NOT screen patients with symptoms of lung cancer

• Symptoms might include otherwise unexplained:
  – Hemoptysis, coughing, shortness of breath
  – Weight Loss, chest pain, hoarseness, bone pains
  – Headaches, vision changes, paraneoplastic syndromes (confusion, nausea, constipation, weakness, clubbing)

• Symptomatic patients should get a diagnostic work-up
  – If CT scan is indicated as part of diagnostic evaluation it should be diagnostic quality CT
    – Chest 2018; 153:954-985
Lung RADS

• Classification of Screening CT scan results
  – 0: incomplete
  – 1: negative: no nodules or nodules with specific benign pattern (ex: granuloma)
  – 2: Benign appearance: nodules with very low likelihood of becoming clinically active cancer (<1% probability of malignancy)
  – 3: Probably Benign: solid nodules less than 8 mm, ground glass less than 20 mm (1-2% probability of malignancy)
  – 4: Suspicious for malignancy
Lung RADS Management

• Groups 1 and 2: low dose CT scan in one year
• Group 3 (probably benign)
  – Repeat CT scan in 6 months
• Group 4 (Suspicious)
  – 4A (subcentimeter nodules): CT scan in 3 months
  – 4B (>15 mm nodule, growing, GGO with solid component>8mm): PET scan, tissue sampling
  – 4X: (above with additional features suggestive of malignancy): tissue sampling
• At Christiana, refer to Cancer Center MDC for Group 4
Nonsurgical Biopsies

1. Bronchoscopic Approaches to lung nodule diagnosis
   - Transbronchial biopsies
   - Yield greatly enhanced with use of navigational bronchoscopy and radial probe endobronchial ultrasound

2. CT Guided Biopsies
   - High yield especially for peripheral lesions, pneumothorax risk

3. SAMPLING ERROR
   - Biopsy are diagnostic when cancer or a benign disease (i.e. Sarcoid) is diagnosed
   - Otherwise they are nondiagnostic
   - A nondiagnostic biopsy does not rule out cancer
Incidental Findings

- Pulmonary findings (70%, n-223)
  - Emphysema (n-162), vocal cord lesion (n-1), bronchial wall thickening (n-126)
- Cardiovascular (68%, n-216)
  - Coronary artery calcification (n-182), Aortic calcification (n-66), aortic dilation (n-28)
- Genitourinary (4%, n-14)
  - Renal cyst (n-8), renal stone (n-4), renal mass (n-2)
- GI (24%, n-79)
  - Hiatal hernia (n-30), liver cyst (n-22), dilated esophagus (n-7), gallstone (n-6)
- Endocrine
  - Adrenal nodule (n-12), thyroid nodule (n-11)
- Other
  - DJD (n-74), compression fx (n-3), breast nodule (n-1), splenic lesion (n-1)
Lung Cancer Screening Conclusion

- Screen: Asymptomatic Adults, 55-80 years old, ≥ 30 pack year history of smoking, Current smoker or quit smoking <15 years ago
- Don’t use screening CT scans for symptomatic patients
- Be prepared for incidental findings
- Consider developing screening program with multidisciplinary group
COPD Update
Diagnostic Instability of COPD

COPD

Normal

COPD

Normal

Normal

COPD

Normal
Diagnostic Instability of COPD

• Spirometry can change over time
• Particular around normal range (FEV1/FVC 0.6 to 0.8)
• Around FEV1/FVC 0.7 => 40% changed from obstructive to normal or vice versa
• 2018 GOLD guidelines update: repeat spirometry on pts with FEV1/FVC 0.6-0.8
• AJRCC 2017; 196: 306-314
GOLD COPD

• Group A
  – No hospitalization, minimal symptoms

• Group B
  – No hospitalization, some symptoms

• Group C
  – 1 hospitalization or ≥2 exacerbation, symptoms controlled

• Group D
  – 1 hospitalization, ≥2 exacerbations, worse symptoms
Figure 4.1. Pharmacologic treatment algorithms by GOLD Grade [highlighted boxes and arrows indicate preferred treatment pathways]

Group C

- LAMA + LABA
- LABA + ICS
- Further exacerbation(s)
- LAMA

Group D

- Consider roflumilast if FEV₁ < 50% pred. and patient has chronic bronchitis
- Consider macrolide (in former smokers)
- Further exacerbation(s)
- LAMA + LABA + ICS
- Persistent symptoms/further exacerbation(s)
- LAMA
- LAMA + LABA
- LABA + ICS

Group A

- Continue, stop or try alternative class of bronchodilator
- evaluate effect
- A bronchodilator

Group B

- LAMA + LABA
- Persistent symptoms
- A long-acting bronchodilator (LABA or LAMA)

Preferred treatment

In patients with a major discrepancy between the perceived level of symptoms and severity of airflow limitation, further evaluation is warranted.

© 2017 Global Initiative for Chronic Obstructive Lung Disease
Role of ICS in COPD

• 4 trials with severe disease (GOLD group D)
  – IMPACT (NEJM 2018; 378: 1671-1680)
  – TRIBUTE (Lancet 2018; 391: 1076-1084)
  – FLAME (NEJM 2016; 374: 2222-2234)

• FLAME showed LAMA/LABA to be better than LAMA/LABA/ICS but excluded patient with hx of asthma and high eosinopils

• The other 3 trials showed benefit with adding ICS
What’s new with ICS in COPD

• Eosinophils
  – Higher the eosinophils the more likely pts seem to be to benefit from ICS
  – KRONOS showed threshold for benefit of 100 (threshold met by 80% of patients)
  – No guidelines on how to use eosinophil count
    • May be something to watch when withdrawing steroids in stable severe patient
    • Also if you have pt with high eosinophil count, may be more likely to benefit from starting steroids
Non-Pharmacologic Treatment

Interventional bronchoscopy and surgery

• In selected patients with heterogeneous or homogenous emphysema and significant hyperinflation refractory to optimized medical care, surgical or bronchoscopic modes of lung volume reduction (e.g., endobronchial one-way valves or lung coils) may be considered.

• In selected patients with a large bulla, surgical bullectomy may be considered.

• In selected patients with very severe COPD and without relevant contraindications, lung transplantation may be considered.
Bronchial Valves

- 2 trials this year:
  - LIBERATE (AJRCCM 2018 May 22. epub ahead of print)
  - TRANSFORM (AJRCCM 2017; 196: 1535-1543)

- Compared valve versus standard of care
  - 48-55% improvement FEV1, QOL, NNT 2-3
  - 1/3 had pneumothorax
  - All stayed overnight in hospital but some pneumothoraces occurred after hospital discharge
  - 2.6% procedure related deaths

- Pros: improved quality of life, improved exercise function
- Cons: pneumothorax and death
NIPPV in COPD

• Clear long-standing benefit for:
  – Acute exacerbation with hypercarbia
    • Sweet spot: pH 7.25-7.35
    • <7.25 can be tried higher risk of failure
  – Co-morbid sleep disorder breathing
    • GOLD guidelines indicate improvement of survival and reduced hospitalization

• Newer in GOLD guidelines stable outpatient with COPD and hypercarbia
  – “NIPPV may improve hospitalization-free survival in selected patients after recent hospitalization, particularly in those with pronounced daytime hypercapnia (PaCO2 ≥ 52 mm Hg)”
NIPPV in stable COPD

• Lancet Respir 2014
  – RCT 116 COPD pts with paCO2 >53 after 2-4 weeks of hospital discharge
  – Home oxygen versus nocturnal NIPPV and oxygen
  – BMI>35, sleep disordered breathing, other causes of respiratory failure were excluded
  – Less re-admissions in NIPPV group
Beta Blockers in COPD

• High incidence of comorbidities such as coronary artery disease, atrial fibrillation, congestive heart failure etc
• Beta blockade benefits these patients. Prefer selective beta-1 blockers (metoprolol, etc)
• Analysis of SUMMIT trial data showed that beta blocker did not increase incidence of COPD exacerbation and did not impact effectiveness of inhaled beta agonist therapy
Figure 1. Time to first exacerbation of chronic obstructive pulmonary disease (COPD) in the (A) absence or (B) presence of β-blocker therapy at baseline. FF = fluticasone furoate, FF/VI = combination of fluticasone furoate and vilanterol; VI = vilanterol.

Annals ATS, 2018
https://www.atsjournals.org/doi/abs/10.1513/AnnalsATS.201708-626OC

Published in: Mark T. Dransfield; David A. McAllister; Julie A. Anderson; Robert D. Brook; Peter M. A. Calverley; Bartolome R. Celli; Courtney Crim; Natacha Gallot; Fernando J. Martinez; Paul D. Scanlon; Julie Yates; Jørgen Vestbo; David E. Newby; Annals ATS 15, 608-614. DOI: 10.1513/AnnalsATS.201708-626OC
Copyright © 2018 by the American Thoracic Society
COPD Update Conclusion

- Spirometric diagnosis of COPD may change – consider re-evaluation in some patients
- Inhaled steroids have role in COPD, particular for patients with high eosinophils, but only in those with significant symptoms and exacerbations (GOLD groups C and D)
- Refer patients with heterogeneous emphysema on CT scans to centers with capability to do bronchial valves and lung volume reduction surgery for evaluation
- Outpatient nocturnal NIPPV benefits stable COPD patients with persistent hypercarbia (paCO2 ≥ 52)
- Beta blockers (beta 1 selective) are safe and effective in COPD patients with cardiovascular indication for their use
Thank You